Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New Name for Acomplia?

This article was originally published in RPM Report

Executive Summary

Sanofi-Aventis is facing a possible name change for rimonabant in the US market. For a much-anticipated primary care product like Acomplia, that's not good news. Sanofi has sent mixed signals as to whether FDA will accept "Acomplia" as the brand name for rimonabant, but all signs indicate that the company will have to choose an alternate name for the US market.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel